1. Medtech Insight
  2. >>Archive

Karl Storz, InTouch to create remote presence tools

 
• By Joseph Harvey

Karl Storz Endoscopy-America (El Segundo, California) and remote presence specialist InTouch Health are set to develop technology designed to provide remote surgeons with the ability to monitor surgical procedures. Under a definitive agreement, InTouch will adapt its remote presence technology into a telemonitoring device that will be compatible with Karl Storz’s OR1 integrated operating room system. The combined technology, which will be called VisitOR1, will also be compatible with Santa Barbara, California-based InTouch’s RP-7 remote presence robotic system, enabling physicians to connect to hospital emergency departments, critical care units and the operating room from a remote location. Financial terms of the deal were not disclosed.

Karl Storz Endoscopy-America (El Segundo, California) and remote presence specialist InTouch Health are set to develop technology designed to provide remote surgeons with the ability to monitor surgical procedures. Under a definitive agreement, InTouch will adapt its remote presence technology into a telemonitoring device that will be compatible with Karl Storz’s OR1 integrated operating room system. The combined technology, which will be called VisitOR1, will also be compatible with Santa Barbara, California-based InTouch’s RP-7 remote presence robotic system, enabling physicians to connect to hospital emergency departments, critical care units and the operating room from a remote location. Financial terms of the deal were not disclosed.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Execs On The Move: 26-30 May 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Where Do Questions Surrounding The EU’s AI Act Leave The Medtech Industry?

 
• By Amanda Maxwell

The EU’s Artificial Intelligence Act, which entered into force on 1 August 2024, is already facing turbulence.

HistoSonics’ Edison System Gains Limited UK Access, While Awaiting CE Marking

 
• By Shubham Singh

While HistoSonics is awaiting the CE mark in Europe, it hit a major milestone by securing early limited market access in Great Britain under a Unmet Clinical Need Authorization (UCNA), bringing its noninvasive histotripsy treatment to patients with liver tumors.